Back to Trades
Other4
Anika Therapeutics, Inc.
ANIK
Total Value
$275.5K
Company Information
- Company Name
- Anika Therapeutics, Inc.
- Ticker Symbol
- ANIK
- CIK
- 0000898437
Insider Information
- Name
- McLeod Ian
- Role
- Insider
- Location
- BEDFORD, MA
Filing Details
- Filing Date
- Mar 23, 2026
- Transaction Date
- Mar 19, 2026
- Accession Number
- 0001193125-26-120005
- Form Type
- 4
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Mar 19, 2026 | Derivative | 13,097 | — | Grant/Award | — |
| Mar 19, 2026 | Derivative | 11,194 | — | Grant/Award | — |
| Mar 19, 2026 | Derivative | 17,663 | $15.60 | Grant/Award | $275.5K |
Footnotes
- (F1)Each Restricted Stock Unit ("RSU") represents the contingent right to receive, at the Issuer's discretion, one share of the Issuer's common stock, or the cash equivalent of the closing price of one share of the Issuer's common stock, on each vest date, in accordance with the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended (the "2017 Plan"), and the applicable award agreement.
- (F2)Vests in three equal annual installments, with the first installment vesting on March 19, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.
- (F3)Vests fully on March 19, 2029, subject to the Reporting Person's continuous service to the Issuer as of such date.
- (F4)Represents a Premium Priced Stock Appreciation Right ("PPSAR") granted under the 2017 Plan. The PPSAR exercise price per share is equal to 110% of the Fair Market Value (as defined in the 2017 Plan) of a share of common stock on the Grant Date. The PPSAR vests in three equal annual installments beginning March 19, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. The PPSAR is payable in cash, shares of common stock, or a combination thereof, at the Issuer's discretion, in accordance with the 2017 Plan, as amended, and the applicable award agreement.